Convatec GroupLSE:CTEC -0.09%77 Days Payable is 97.38 as of Dec. 2025, which is 118% above its 10-year median of 44.74. GuruFocus rates LSE:CTEC with a GF Score™ of 77/100 and a GF Value™ of £2.55 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Convatec Group ranks better than 57.74% on this metric.
The historical rank and industry rank for Convatec Group's Days Payable or its related term are showing as below:
LSE:CTEC'
s Days Payable Range Over the Past 10 Years
Min: 38.27 Med: 44.74 Max: 81.81
Current: 81.81
During the past 13 years, Convatec Group's highest Days Payable was 81.81. The lowest was 38.27. And the median was 44.74.
LSE:CTEC's Days Payable is ranked better than 57.74% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs LSE:CTEC: 81.81
Convatec Group's Days Payable
increased
from Dec. 2024 (78.38) to Dec. 2025 (97.38).
It may suggest that Convatec Groupdelayed paying its suppliers.
Convatec Group Days Payable Related Terms
Convatec Group Days Payable Historical Data
* Premium members only.
The historical data trend for Convatec Group's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:CTEC vs ISRG, BDX, MDLN: Days Payable Comparison
For the Medical Instruments & Supplies subindustry, Convatec Group's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Convatec Group Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Convatec Group's Days Payable distribution charts can be found below:
* The bar in red indicates where Convatec Group's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Convatec Group's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Convatec Group (LSE:CTEC) has a Days Payable of 97.38 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Convatec Group and its competitors. This is 118% above median its historical median of 44.74. Over the past decade, Convatec Group's Days Payable has ranged from 38.27 to 81.81. According to the industry distribution chart, Convatec Group ranks #336 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 42.3%.
Is Convatec Group's Days Payable too high?
Convatec Group's current Days Payable of 97.38 is 118% above median its 10-year median of 44.74. Over the past 10 years, this metric has ranged from a low of 38.27 to a high of 81.81. The Medical Devices & Instruments industry median Days Payable is 68.07. Convatec Group's value of 97.38 is 43.1% above this industry median. Based on the distribution chart, Convatec Group ranks #336 out of 795 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Convatec Group has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Convatec Group's Days Payable compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Convatec Group ranks #336 out of 795 companies for Days Payable. This puts Convatec Group in the upper half of its industry. The industry median Days Payable is 68.07. Convatec Group's value of 97.38 is 43.1% above this benchmark. Historically, Convatec Group's own Days Payable has ranged from 38.27 to 81.81 over the past decade. While the company's 10-year median is 44.74 vs. the industry median of 68.07, Convatec Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Convatec Group's current Days Payable of 97.38 is 43.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Convatec Group and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Convatec Group's current Days Payable is 97.38, which is 118% above median its own 10-year median of 44.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Convatec Group stock overvalued right now?
Based on GuruFocus' analysis, Convatec Group (LSE:CTEC) is currently considered Modestly Undervalued. The stock's GF Value™ is £2.55, compared to a current price of £2.12 — trading 17% below its estimated fair value. The current Days Payable is 97.38, which is 118% above median its 10-year median of 44.74 and 43.1% above the Medical Devices & Instruments industry median of 68.07. Convatec Group's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Convatec Group (LSE:CTEC), the current Days Payable is 97.38 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Convatec Group (LSE:CTEC) Overvalued in 2026?
Based on GuruFocus' analysis, Convatec Group stock appears to be undervalued.
The current stock price of £2.12 is trading 17% below its estimated GF Value™ of £2.55.
GuruFocus considers Convatec Group to be Modestly Undervalued.
Key valuation signals for LSE:CTEC:
Days Payable: 97.38 (118% above median its 10-year median of 44.74)
GF Value™: £2.55 vs. price of £2.12 (17% below fair value)
Industry Position: 43.1% above the Medical Devices & Instruments median (#336 of 795)
No single metric tells the full story. See the LSE:CTEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 32% and 28% of total revenue, respectively. Continence care has become a slightly smaller business (22% of revenue) following the decision to exit the acute care market, and infusion sets contribute 18% of consolidated revenue.
77GF Score
Get the complete analysis for LSE:CTEC
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:CTEC has been successfully added to your 
